Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698684 · ClinicalTrials.gov registry record · Phase 4
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
A Phase 4 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 4
- Development phase
- 440
- Enrollment target
NCT01698684: Completed Phase 4 study, sponsored by VIVUS.
NCT01698684 is a Phase 4 study that has completed, run by VIVUS. The registered enrollment target is 440 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01698684, a Phase 4 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 440 participants
- Enrollment target
Study Summary
The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction
Interventions
- DRUG Placebo
- DRUG Avanafil 100 mg
- DRUG Avanafil 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01698684 record still lists
NCT01698684 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01698684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01698684 about?
NCT01698684 is a clinical study titled "Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction". The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction
What is the current status of trial NCT01698684?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 440 participants. The study started on 2012-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01698684?
The interventions under investigation include: Placebo (DRUG), Avanafil 100 mg (DRUG), Avanafil 200 mg (DRUG).
Who is sponsoring clinical trial NCT01698684?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01698684's enrollment target sits among peer trials
440 190th of 2000 higher than 1,810 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia